Dear EVER members,
As EVER president it is my pleasure and a privilege to invite you to the 2013 EVER meeting in Nice, France. Our 2012 meeting inaugurated this Congress venue, and judging from the broad attendance, one can only conclude that many EVER members consider this location to be a very convenient one.
During the last decade ophthalmology has witnessed many important changes : the pathogenesis of wet AMD is better understood and we start to have effective treatment; pharmacological interventions for vitreoretinal interface pathology are now a fact; thanks to innovative therapies we will be able to postpone or to avoid surgery in a substantial number of patients with keratoconus; cataract surgery will probably move from manual surgery to laser surgery in the near future; and last but not least, the first results of gene therapy for retinal dystrophies in humans have been published in the last years. These are just a few examples to illustrate how the constant progress in basic science and the results of translational and clinical research have a major impact on the way we tackle blindness and vision loss in our patients. The great thing about the EVER meeting is that it provides a platform for discussion to all those who participate in this complex process that leads to progress in Visual Science and Ophthalmology: from the basic scientist to the highly subspecialized clinician, from the young PhD student to the internationally renowned expert. The informal atmosphere at EVER and the ample opportunity for discussion during the conference create a favourable climate for dialogue and cross-fertilization. It is our hope that future European collaborations and projects may be initiated at the EVER meetings.
This year’s programme brings the usual combination of Special Interest Symposia from the eleven EVER sections, seventeen Courses, Key Note lectures some delivered by world class scientists, joint meetings with twelve other Groups, Clubs or Societies, and of course traditional poster sessions with opportunity for face-to-face discussion. It is not always easy to strike the right balance between basic science and clinical research, but the Board members are aware of this issue and will monitor it in the future.
While I am sure that the quality of the scientific programme is our prime concern, I am equally convinced that most EVER members will greatly appreciate the charms, the climate and the surroundings of Nice, an ideal setting for the social activities of the EVER meeting. The social programme in 2013 will try to involve as many participants as possible and I look forward to share these moments with you.
President EVER 2013